Health Care · Hospital & Medical Service Plans

HUM Humana SEC Filings & Insider Trading Activity 2026

company
CIK 49071110 filings
S&P 500

HUM at a glance

Humana (HUM, SEC CIK 49071) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Humana (HUM) reported revenue of $129.7 billion (up 10.1% from FY2024) and net income of $1.2 billion. Diluted EPS was $9.84.
  • As of September 30, 2026, 44 institutional investment managers tracked by SignalX reported holding Humana (HUM) shares worth $17.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Frederick Wayne A.I. on November 10, 2026 of 440 shares at $440.57 per share.
  • In the last 90 days, HUM insiders reported 0 open-market purchases ($0) and 2 open-market sales ($2.6M) on Form 4, a net sale of $2.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$129.7B
+10.1% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$2.6M
13F holders
44 funds
$17.8B · +1 vs prior quarter
Latest 8-K
Nov 17, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Integrated health insurance services primarily delivering Medicare Advantage and Medicaid plans with complementary healthcare services via CenterWell
  • New emphasis on Medicare Advantage individual plans covering 5.2 million members, including approx. 1.0 million in Florida generating $17.8B premiums (20% of individual MA revenue)
  • Strategic focus on transitioning providers from fee-for-service to value-based care, enhancing integrated care and member engagement through data analytics
  • Medicare Advantage premiums and services revenue $106.3B, comprising 82.6% of segment total; 83% of total revenue derived from federal contracts, CMS-partnered
  • Noteworthy: Renewed all Medicare Advantage contracts for 2026, including expanded Florida presence accounting for 14% of consolidated premiums and services revenue

Management Discussion & Analysis

  • Revenue $129.7B, up 10.1% YoY; premiums $122.8B (+9.6%), services $5.8B (+31.6%), investment income down 17.9% to $1.0B
  • Net income $1.2B, flat YoY (-0.9%); operating margin 2.1% (operating income $2.7B on $129.7B revenue) vs 2.2% in 2024
  • Best performing segment: Insurance income from operations $1.7B, up 29.1% on premiums $122.8B; worst: CenterWell flat at $1.3B income despite 12.7% revenue growth
  • Benefit ratio 90.2% vs 89.8%; Operating cost ratio increased to 12.0% from 11.8% driven by CenterWell segment; Insurance cost ratio fell slightly to 9.1%
  • Value creation charges $449M in 2025; impairments $253M; capital spending reduced (depreciation down 16.8% to $698M)
  • Cash flow: No specific CAPEX, dividend, or buyback $ disclosed; operating cash flow seasonally impacted by Medicare design changes
  • 2026 outlook: Anticipate Medicare Advantage membership growth (~25% individual, 150k group), PDP growth ~1M; risks from regulatory changes and pricing pressures noted

Risk Factors

  • CMS 2025 Medicare Advantage Star Ratings declined, risking lower 2026 quality bonus payments and revenues due to pending lawsuit outcome
  • Exposure to geopolitical climate risk from frequent/intense catastrophes including pandemics and hurricanes affecting medical cost trends
  • Dependency on third-party IT providers for critical data services risks service disruptions and contract adversities
  • Competitive pressure from larger insurers and emerging entrants intensifies premium price containment challenges
  • Lawsuit exposure under False Claims Act for Medicare risk-adjustment practices with potential for treble damages and insurance coverage gaps

AI summary of the HUM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $41.2B, up 26.1% YoY from $32.6B, driven by Medicare membership and CenterWell growth
  • Benefit ratio 93.9% vs 91.1%; operating cost ratio 11.3% vs 12.6%
  • Best segment: CenterWell revenue $1.9B, up 40.4%; worst: Insurance loss $303M vs $251M income
  • Cash $6.9B vs $4.2B at December 31; operating cash flow $5.4B vs $2.6B
  • MaxHealth acquisition $908M; management expects significant operating cash outflows in remainder of 2026

AI summary of the HUM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 17, 2026Full analysis →

Item 8.01: Other Events

  • Humana announced pricing terms for its cash tender offer covering certain outstanding debt securities
  • Tender offer expired November 16, 2026, with results disclosed in Exhibit 99.2

Item EX-99.1: Item EX-99.1

  • Cash tender offers target up to $1.5B of outstanding debt, reducing Humana’s funded obligations if fully completed
  • Acceptance priority favors 2.150% 2032 notes through 3.950% 2027 notes, creating potential proration for lower-priority tenders

Item EX-99.2: Item EX-99.2

  • Humana completed cash tenders for seven debt series, accepting approximately $1.47B principal across fully accepted notes
  • April 2031 Notes: $858.514M tendered, $198.661M accepted at approximately 23.74% proration
Filed Nov 9, 2026Full analysis →

Item 8.01: Other Events

  • Humana launched a cash tender offer for certain outstanding debt securities
  • The offer could reduce or refinance debt, potentially affecting interest expense and leverage

Item EX-99.1: Item EX-99.1

  • Humana launched cash tenders for eight debt series, targeting up to $1.5B of aggregate purchase price
  • Highest priority: 2.150% 2032 notes, followed by 3.125% and 3.700% 2029 notes
Filed Nov 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Humana reported financial results for the quarter ended September 30, 2026
  • Detailed earnings release attached as Exhibit 99.1 and Exhibit 99.2

Item 7.01: Regulation FD Disclosure

  • Q3 2026 financial results released for quarter ended September 30, 2026
  • Detailed earnings release available in Exhibit 99.2 and Humana Investor Relations

Item EX-99.3: Item EX-99.3

  • FY 2026 Adjusted EPS guidance raised from at least $9.00 to at least $9.50, signaling stronger near-term earnings momentum
  • 3Q26 Adjusted loss per share of $0.70 beat expected loss of approximately $1.00, driven by Insurance performance

Item EX-99.1: Item EX-99.1

  • 3Q26 GAAP EPS $1.33, down from $1.62, while Adjusted loss per share was $0.70 versus $3.24 adjusted earnings
  • Insurance benefit ratio 93.7%, better than guidance of slightly above 94%, but segment operating income fell to a $303 million loss

Item EX-99.2: Item EX-99.2

  • 3Q26 revenue $41.2B, up from $32.6B, but adjusted loss $0.70 per share versus $3.24 earnings
  • Insurance benefit ratio 93.7%, better than guidance of slightly above 94%, despite Star Ratings revenue pressure

AI summaries of HUM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HUM

Don't miss the next HUM filing

  • Alerts as it files. A push when HUM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HUM, by share count.
  • Ask anything. An AI agent that reads every HUM filing and answers with sources.

HUM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Dintenfass DavidGNov 10, 2026-
Frederick Wayne A.I.SellNov 10, 2026$440.57
Ventura Joseph CSellNov 9, 2026$433.85
Ventura Joseph CGNov 9, 2026-
HILZINGER KURT JASep 30, 2026$384.91
Nundy ShantanuASep 1, 2026-
Smith Paul JohnAAug 1, 2026-
Crawford Frederick JohnAAug 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$117.8B$129.7B
Operating Income-$2.6B$2.7B
Net Income$2.5B$1.2B$1.2B
Op. Margin-2.2%2.1%
Net Margin-1.0%0.9%
Balance Sheet
Total Assets$47.1B$46.5B$48.9B
Equity-$16.4B$17.7B
ROE-7.4%6.7%
Per Share
EPS$20.00$9.98$9.84
Cash Flow
Operating CF-$3.0B$921.0M
CapEx$1.0B$575.0M$546.0M

Source: XBRL data in Humana (HUM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HUM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HUM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202644$17.80B
Q2 202643$18.85B
Q1 202641$8.21B
Q4 202542$13.60B
Q3 202543$15.96B
Q2 202541$13.21B
Q1 202537$11.27B
Q4 202434$8.88B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 325 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HUM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 17, 2026Analysis-
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
8-KNov 9, 2026Analysis-
8-KNov 6, 2026Analysis-
10-QNov 6, 2026Analysis
8-KOct 13, 2026Analysis-
8-KOct 9, 2026Analysis-
4Oct 2, 2026--
4Sep 3, 2026--
8-KSep 1, 2026Analysis-
4Aug 4, 2026--
4Aug 4, 2026--
10-QJul 29, 2026Analysis
8-KJul 29, 2026Analysis-
8-KJul 29, 2026Analysis-
8-KJun 1, 2026Analysis
8-KMay 19, 2026Analysis
4May 5, 2026--
4May 5, 2026--
4May 5, 2026--
4May 5, 2026--
4May 5, 2026--
4May 5, 2026--

Related Health Care companies

All Health Care →

HUM SEC filings: frequently asked questions

Are HUM insiders buying or selling?

In the last 90 days, Humana (HUM) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $2.6 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold HUM stock?

As of September 30, 2026, the largest Humana (HUM) holders among the 13F filers tracked by SignalX were BlackRock ($4.1 billion), Vanguard Capital Management LLC ($3.0 billion), Vanguard Portfolio Management LLC ($2.2 billion), State Street Corp ($2.1 billion), JPMorgan Chase & Co ($1.5 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HUM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Humana (HUM) reported revenue of $129.7 billion (up 10.1% from FY2024) and net income of $1.2 billion. Diluted EPS was $9.84. The figures come from the XBRL data in the 10-K.

What are the main risks in HUM's latest 10-K?

In the 10-K filed February 19, 2026, Humana (HUM) flagged: CMS 2025 Medicare Advantage Star Ratings declined, risking lower 2026 quality bonus payments and revenues due to pending lawsuit outcome. Exposure to geopolitical climate risk from frequent/intense catastrophes including pandemics and hurricanes affecting medical cost trends. (AI summary of the Risk Factors section.)

What did HUM report in its latest 8-K?

Humana (HUM) filed an 8-K on November 17, 2026 reporting Item 8.01 (Other Events). Humana announced pricing terms for its cash tender offer covering certain outstanding debt securities.

What are the latest HUM SEC filings?

Humana (HUM) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on November 12, 2026.

What is HUM's SEC CIK number?

Humana (HUM)'s SEC Central Index Key (CIK) is 49071. EDGAR lists every HUM filing under that number.

Ask anything about HUM

The research agent reads HUM's filings, financials, insider trades and 13F holders, then answers with sources.